Possible role of GLP-1 and its agonists in the treatment of type 1 diabetes mellitus

Current Diabetes Reports

Volumn 12, Issue 5, 2012, Pages 560-567

  Issa, Claire M ^a   Azar, Sami T ^a  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

Author keywords

GLP 1; Glucagon; Glycemic control; Insulin; Type 1 diabetesmellitus

Indexed keywords

ARGININE; C PEPTIDE; EXENDIN 4; GASTRIN; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GLUCAGON LIKE PEPTIDE 2; GLUCOSE; INSULIN; LISOFYLLINE; LYMPHOCYTE ANTIBODY; PLACEBO;

APOPTOSIS; ARTICLE; CELL PROLIFERATION; CONTINUOUS INFUSION; DIETARY INTAKE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; GLUCOSE BLOOD LEVEL; GLUCOSE TRANSPORT; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; INSULIN RESISTANCE; MEDLINE; MORNING DOSAGE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PANCREAS ISLET CELL FUNCTION; PATHOPHYSIOLOGY; POSTPRANDIAL STATE; PROTEIN FUNCTION; PROTEIN INTERACTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIGNAL TRANSDUCTION; STOMACH EMPTYING; TREATMENT DURATION;

EID: 84870787581     PISSN: 15344827     EISSN: 15390829     Source Type: Journal    
DOI: 10.1007/s11892-012-0291-6     Document Type: Article

References (78)

1. Bayliss WM, Starling EH. Mechanism of pancreatic secretion. J Physiol. 1902;28:235-334.
2. Loew ER, Gray JS, Ivy AC. Is a duodenal hormone involved in carbohydrate metabolism? Am J Physiol. 1940;129:659-63.
3. Loew ER, Gray JS, Ivy AC. The effect of duodenal instillation of hydrochloric acid upon the fasting blood sugar of dogs. Am J Physiol. 1939;126:270-6.
4. Loew ER, Gray JS, Ivy AC. The effect of acid stimulation of the duodenum upon experimental hyperglycemia and utilization of glucose. Am J Physiol. 1940;128:298-308.
5. Elrick H, Stimmler L, Hlad CJ, Arai Y. Plasma insulin responses to oral and intravenous glucose administration. J Clin Endocrinol Metab. 1964;24:1076-82.
6. Mcintryre N, Holdsworth CD, Turner DA. New interpretation of oral glucose tolerance. Lancet. 1964;II:20-1.
7. Brown JC. A gastric inhibitory polypeptide. I. The amino acid composition and the tryptic peptides. Can J Biochem. 1971;49:255-61.
8. Brown JC, Dryburgh Jr. A gastric inhibitory polypeptide. II. The complete amino acid sequence. Can J Biochem. 1971;49:867-72.
9. Brown JC, Mutt V, Pederson RA. Further purification of a polypeptide demonstrating enterogastrone activity. J Physiol. 1970; 209:57-64.
10. Dupreo J, Ross SA, Watson D, Brown JC. Stimulation of insulin secretion by gastric inhibitory polypeptide in man. J Clin Endocrinol Metab. 1973;37:826-28.
11. Bell GI, Sanchez-Pescador R, Laybourn PJ, Najarian RC. Exon duplication and divergence in the human preproglucagon gene. Nature. 1983;304:368-71. (Pubitemid 13072761)
12. Schmidt WE, Siegel EG, Creutzfeldt W. Glucagonlike peptide-1 but not glucagon-like-peptide-2 stimulates insulin release from isolated rat pancreatic islets. Diabetologia. 1985;28:704-7. (Pubitemid 16226411)
13. Mojsov S, Weir GC, Habener JF. Insulinotropin glucagon-like peptide-1 (7-36): co-encoded in the glucagons gene is a potent stimulator of insulin release in the perfused rat pancreas. J Clin Invest. 1987;79:616-19. (Pubitemid 17009701)
14. Meier JJ, Hucking K, Holst JJ, Deacon CF, Schmiegel WH, Nauck MA. Reduced insulinotropic effect of gastric inhibitory polypeptide in first-degree relatives of patients with type 2 diabetes. Diabetes. 2001;50:2497-504. (Pubitemid 33642767)
15. Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R, Creutzfeldt W. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest. 1993;91:301-7. (Pubitemid 23037285)
16. Drucker DJ, Erlich P, Asa SL, Brubaker PL. Induction of intestinal epithelial proliferation by glucagon-like peptide 2. Proc Natl Acad Sci USA. 1996;93:7911-16. (Pubitemid 26277138)
17. Drucker DJ, Yusta B, Boushey RP, Deforest L, Brubaker PL. Human [Gly2]GLP-2 reduces the severity of colonic injury in a murine model of experimental colitis. Am J Physiol. 1999;276:G79-91. (Pubitemid 29063603)
18. Rocca AS, Lagreca J, Kalitsky J, Brubaker PL. Monounsaturated fatty acid diets improve glycemic tolerance through increased secretion of glucagon-like peptide-1. Endocrinology. 2001;142:1148-55. (Pubitemid 32202825)
19. Thomsen C, Storm H, Holst JJ, Hermansen K. Differential effects of saturated and monounsaturated fats on postprandial lipemia and glucagon-like peptide 1 responses in patients with type 2 diabetes. Am J Clin Nutr. 2003;77:605-11. (Pubitemid 36258569)
20. Sakurai H, Dobbs RE, Unger RH. The effect of somatostatin on the response of GLI to the intraduodenal administration of glucose, protein, and fat. Diabetologia. 1975;11:427-30.
21. Matsuyama T, Hoffman WH, Dunbar JC, Foa NL, Foa PP. Glucose, insulin, pancreatic glucagon and glucagon-like immunoreactive materials in the plasma of normal and diabetic children. Effect of the initial insulin treatment. Horm Metab Res. 1975; 7:452-6.
22. Balks HJ, Holst JJ. Von Zur Muhlen A, Brabant G. Rapid oscillations in plasma glucagon-like peptide-1 (GLP-1) in humans: cholinergic control of GLP-1 secretion via muscarinic receptors. J Clin Endocrinol Metab. 1997;82:786-90. (Pubitemid 27106588)
23. Dumoulin V, Dakka T, Plaisancie P, Chayvialle JA, Cuber JC. Regulation of glucagon-like peptide-1-(7-36) amide, peptide YY, and neurotensin secretion by neurotransmitters and gut hormones in the isolated vascularly perfused rat ileum. Endocrinology. 1995;136:5182-88.
24. Lickley HL, Kemmer FW, Gray DE, et al. Chromatographic pattern of extrapancreatic glucagons and glucagon-like immunoreactivity before and during stimulation by epinephrine and participation of glucagons in epinephrine-induced hepatic glucose overproduction. Surgery. 1981;90:186-94. (Pubitemid 11047229)
25. Eng J, Kleinman WA, Singh L, Singh G, Raufman JP. J Biol Chem. 1992;267:7402-5.
26. Devendra D, Liu E, Eisenbarth GS. Type 1 diabetes: recent developments. BMJ. 2004;328:750-4. (Pubitemid 38406430)
27. Madsbad S, Krarup T, Regeur L, Faber OK, Binder C. Insulin secretory reserve in insulin dependent patients at time of diagnosis and the first 180 days of insulin treatment. Acta Endocrinol (Copenh). 1980;95:359-63. (Pubitemid 11211731)
28. Madsbad S. Prevalence of residual B cell function and its metabolic consequences in Type 1 (insulin-dependent) diabetes. Diabetologia. 1983;24:141-7. (Pubitemid 13147816)
29. Dinneen S, Alzaid A, Turk D, Rizza R. Failure of glucagon suppression contributes to postprandial hyperglycaemia in IDDM. Diabetologia. 1995;38:337-43.
30. Greenbaum CJ, Prigeon RL, D'Alessio DA. Impaired beta-cell function, incretin effect, and glucagon suppression in patients with type 1 diabetes who have normal fasting glucose. Diabetes. 2002;51:951-7. (Pubitemid 34438336)
31. Lugari R, Dell'Anna C, Ugolotti D, et al. Effect of nutrient ingestion on glucagon-like peptide 1 (7-36 amide) secretion in human type 1 and type 2 diabetes. Horm Metab Res. 2000; 32:424-8.
32. Vilsboll T, Krarup T, Sonne J, et al. Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus. J Clin Endocrinol Metab. 2003; 88:2706-13. (Pubitemid 36724446)
33. Varga T, Firneisz G, Nagy G, Somogyi A. Elevated serum DPP4 activity in type 1 diabetes mellitus: a direct comparison. Orv Hetil 2010 151: 899-902.
34. Creutzfeldt WO, Kleine N, Willms B, Orskov C, Holst JJ, Nauck MA. Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I (7-36) amide in type I diabetic patients. Diabetes Care. 1996;19:580-6.
35. Meier JJ, Nauck MA. Glucagon-like peptide 1(GLP-1) in biology and pathology. Diabetes Metab Res Rev. 2005;21:91-117. (Pubitemid 40467658)
36. GutniakM, Orskov C, Holst JJ, Ahren B, Efendic S. Antidiabetogenic effect of glucagon-like peptide-1 (7-36) amide in normal subjects and patients with diabetes mellitus. N Engl J Med. 1992; 326:1316-22.
37. Dupre J, Behme MT, Hramiak IM, et al. Glucagon-like peptide I reduces postprandial glycemic excursions in IDDM. Diabetes. 1995;44:626-30.
38. Dupre J, Behme MT, Hramiak IM, McDonald TJ. Subcutaneous glucagon-like peptide I combined with insulin normalizes postcibal glycemic excursions in IDDM. Diabetes Care. 1997;20:381-4. (Pubitemid 27098228)
39. Behme MT, Dupre J, McDonald TJ. Glucagon-like peptide 1 improved glycemic control in type 1 diabetes. BMC Endocr Disord. 2003;10:1-9.
40. Raman VS, Mason KJ, Rodriguez LM, Hassan K, Yu Xi, Bomgaars L, et al. The role of adjunctive exenatide therapy in pediatrics type 1 DM. Diabetes Care 2010;33(6):1294-6.
41. Kielgast A, Madsbad H. Effect of GLP-1 on alfa and beta-cell function in c-peptide negative type 1 diabetic patients. J Clin Endocrin Metab 2010;95(5):2492-6.
42. Villanueva-Penacarrillo ML, Alcantara AI, Clemente F, Delgado E, Valverde I. Potent glycogenic effect of GLP-1(7-36)amide in rat skeletal muscle. Diabetologia. 1994;37:1163-6.
43. Merida E, Delgado E, Molina LM, Villanueva-Penacarrillo ML, Valverde I. Presence of glucagon and glucagon-like peptide-1-(7-36) amide receptors in solubilized membranes of human adipose tissue. J Clin Endocrinol Metab. 1993;77:1654-7. (Pubitemid 24000929)
44. Villanueva-Penacarrillo ML, Delgado E, Trapote MA, Alcantara A, Clemente F, Luque MA, et al. Glucagon-like peptide-1 binding to rat hepatic membranes. J Endocrinol. 1995;46:183-9.
45. Morales M, Lopez-Delgado MI, Alcantara AI, Luque MA, Clemente F, Marquez L, et al. Preserved GLP-1 effects on glycogen synthase a activity and glucose metabolism in isolated hepatocytes and skeletal muscle from diabetic rats. Diabetes. 1997;46:1264-9. (Pubitemid 27315273)
46. Lopez-Delgado MI, Morales M, Villanueva-Penacarrillo ML, Malaisse WJ, Valverde I. Effects of glucagon-like peptide 1 on the kinetics of glycogen synthase a in hepatocytes from normal and diabetic rats. Endocrinology. 1998;139:2811-17. (Pubitemid 28512390)
47. Meneilly GS, McIntosh CH, Pederson RA, et al. Effect of glucagonlike peptide 1 (7-36 amide) on insulin-mediated glucose uptake in patients with type 1 diabetes. Diabetes Care. 2003;26:837-42. (Pubitemid 36929352)
48. Vella A, Shah P, Basu R, Basu A, Camilleri M, Schwenk FW, et al. Effect of glucagon-like peptide-1(7-36)-amide on initial splanchnic glucose uptake and insulin action in humans with type 1 diabetes. Diabetes. 2001;50:565-72. (Pubitemid 32195221)
49. Vella A, Shah P, Reed AS, Adkins AS, Basu R, Rizza RA. Lack of effect of exendin-4 and glucagon-like peptide-1-(7-36)-amide on insulin action in nondiabetic humans. Diabetologia. 2002;45:1410-15. (Pubitemid 35244894)
50. Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology. 2007;132:2131-57. (Pubitemid 46711096)
51. Brubaker PL, Drucker DJ. Minireview. Glucagon-like peptides regulate cell proliferation and apoptosis in the pancreas, gut, and central nervous system. Endocrinology. 2004;145:2653-9. (Pubitemid 38686211)
52. Deacon CF. Therapeutic strategies based on glucagon-like peptide. Diabetes. 2004;53:2181-9. (Pubitemid 39145569)
53. Egan JM, Bulotta A, Hui H, Perfetti R. GLP-1 receptor agonists are growth and differentiation factors for pancreatic islet beta cells. Diabetes Metab Res Rev. 2003;19:115-23. (Pubitemid 36417195)
54. List JF, Habener JF. Glucagon-like peptide 1 agonists and the development and growth of pancreatic beta-cells. Am J Physiol Endocrinol Metab. 2004;286:E875-81. (Pubitemid 38668807)
55. Scrocchi LA, Brown TJ, MacLusky N, Brubaker PL, Auerbach AB, Joyner AL, et al. Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene. Nat Med. 1996;2:1254-8. (Pubitemid 26375413)
56. Serre V, Dolci W, Schaerer E, Scrocchi L, Drucker D, Efrat S, et al. Exendin-(9-39) is an inverse agonist of the murine glucagon-like peptide-1 receptor: implications for basal intracellular cyclic adenosine 3,5-monophosphate levels and beta-cell glucose competence. Endocrinology. 1998;139:4448-54. (Pubitemid 28487758)
57. Schirra J, Sturm K, Leicht P, Arnold R, Goke B, Katschinski M. Exendin(9-39)amide is an antagonist of glucagon-like peptide-1(7-36)amide in humans. J Clin Invest. 1998;01:1421-30. (Pubitemid 28166840)
58. Fehmann HC, Habener JF. Insulinotropic hormone glucagon-like peptide-I(7-37) stimulation of proinsulin gene expression and proinsulin biosynthesis in insulinoma beta TC-1 cells. Endocrinology. 1992;130:159-66.
59. Wang Y, Perfetti R, Greig NH, Holloway HW, DeOre KA, Montrose-Rafizadeh C, et al. Glucagon-like peptide-1 can reverse the agerelated decline in glucose tolerance in rats. J Clin Invest. 1997; 99:2883-9. (Pubitemid 27278664)
60. Holz GG, Chepurny OG. Glucagon-like peptide-1 synthetic analogs: new therapeutic agents for use in the treatment of diabetes mellitus. Curr Med Chem. 2003;10:2471-83. (Pubitemid 37236400)
61. Anderson MS, Bluestone JA. The NOD mouse. A model of immune dysregulation. Annu Rev Immunol. 2005;23:447-85. (Pubitemid 40563177)
62. Zhang J, Tokui Y, Yamagata K, et al. Continuous stimulation of human glucagon-like peptide-1 (7-36) amide in a mouse model (NOD) delays onset of autoimmune type 1 diabetes. Diabetologia. 2007;50:1900-9. (Pubitemid 47222856)
63. Hadjiyanni I, Baggio LL, Poussier P, Drucker DJ. Exendin-4 modulates diabetes onset in nonobese diabetic mice. Endocrinology. 2008;149:1338-49. (Pubitemid 351397945)
64. Suarez-Pinzon WL, Power RF, Yan Y, Wasserfall C, Atkinson M, Rabinovitch A. Combination therapy with glucagon-like peptide-1 and gastrin restores normoglycemia in diabetic NOD mice. Diabetes. 2008;57:3281-8.
65. Sherry NA, Chen W, Kushner JA, et al. Exendin-4 improves reversal of diabetes in NOD mice treated with Anti-CD3 monoclonal antibody by enhancing recovery of β-cells. Endocrinology. 2007;148:5136-44. (Pubitemid 350012634)
66. Yang Z, Chen M, Carter JD, et al. Combined treatment with lisofylline and exendin-4 reverses autoimmune diabetes. Biochem Biophys Res Commun. 2006;344:1017-22.
67. Ogawa N, List JF, Habener JF, Maki T. Cure of overt diabetes in NOD mice by transient treatment with anti-lymphocyte serum and exendin-4. Diabetes. 2004;53:1700-5. (Pubitemid 38857027)
68. Perez-Arana G, Blandino-Rosano M, Prada-Oliveira A, Aguilar-Diosdado M, Segundo C. Decrease in beta-cell proliferation precedes apoptosis during diabetes development in Bio-Breeding/Worcester rat: beneficial role of Exendin-4. Endocrinology. 2010;151:2538-46.
69. Liu MJ, Han J, Lee YS, Park MS, Shin S, Jun HS. Amelioration of hyperglycemia by intestinal overexpression of GLP-1 in mice. J Mol Med. 2010;88:351-8.
70. Burcelin R. EuCSGLP-1. What is known, new and controversial about GLP-1? Minutes of the 1st European GLP-1 club meeting, Marseille 28-29 May 2008. Diabetes Metab. 2008;34(6 Pt 1):627-30.
71. Meier JJ. Beta-cell mass in diabetes: a realistic therapeutic target? Diabetologia. 2008;51(5):703-13.
72. Roep BO. Are insights gained from NOD mice sufficient to guide clinical translation? Another inconvenient truth. Ann NY Acad Sci. 2007;1103:1-10. (Pubitemid 46791118)
73. Li Y, Cao X, Li LX, Brubaker PL, Edlund H, Drucker DJ. Beta-cell Pdx1 expression is essential for the glucoregulatory, proliferative, and cytoprotective actions of glucagon-like peptide-1. Diabetes. 2005;54:482-91.
74. Stoffers DA, Kieffer TJ, Hussain MA, et al. Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas. Diabetes. 2000;49:741-8. (Pubitemid 30339989)
75. Suen PM, Li K, Chan JC, Leung PS. In vivo treatment with glucagon-like peptide 1 promotes the graft function of fetal isletlike cell clusters in transplanted mice. Int J Biochem Cell Biol. 2006;38:951-60. (Pubitemid 43363424)
76. Froud T, Faradji RN, Pileggi A, et al. The use of exenatide in islet transplant recipients with chronic allograft dysfunction: safety, efficacy and metabolic effects. Transplantation. 2008;86:36-45.
77. Ghofaili KA, Fung M, Ao Z, et al. Effect of exenatide on beta-cell function after islet transplantation in type 1 diabetes. Transplantation. 2007;15(83):24-8. (Pubitemid 46104966)
78. Faradji RN, Tharavanij T, Messinger S, et al. Long-term insulin independence and improvement in insulin secretion after supplemental islet infusion under exenatide and etanercept. Transplantation. 2008;27(86):1658-65.